Status:
COMPLETED
Study of Blood Samples and Risk of Infection in Patients With Newly Diagnosed Malignant Supratentorial Astrocytoma
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborating Sponsors:
National Cancer Institute (NCI)
North American Brain Tumor Consortium
Conditions:
Brain and Central Nervous System Tumors
Infection
Eligibility:
All Genders
18+ years
Brief Summary
RATIONALE: Gathering information over time from laboratory tests of patients with newly diagnosed malignant supratentorial astrocytoma may help doctors learn more about the effect of treatment on whit...
Detailed Description
OBJECTIVES: * Determine the frequency and severity of decreases in CD4 counts as a function of therapy in patients with newly diagnosed malignant astrocytoma. * Determine whether the decrease in CD4 ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed primary malignant brain tumor in 1 of the following groups:
- High grade (grade III or IV) supratentorial glioma receiving antineoplastic treatment and with 1 of the following histologies:
- Anaplastic astrocytoma
- Glioblastoma multiforme (giant cell glioblastoma or gliosarcoma)
- Anaplastic oligodendroma
- Low grade (grade I or II) supratentorial glioma not planning to receive treatment of any kind (including steroids) and with 1 of the following histologies:
- Astrocytoma
- Oligodendroglioma
- PATIENT CHARACTERISTICS:
- Karnofsky performance status 60-100%
- No HIV positivity
- PRIOR CONCURRENT THERAPY:
- No prior chemotherapy for brain tumor except polifeprosan 20 with carmustine implant (Gliadel® wafer)
- No prior cranial radiotherapy or radiotherapy for brain tumor
- No prior immunotherapy or biologic agents for brain tumor, including any of the following:
- Immunotoxins
- Immunoconjugates
- Peptide receptor antagonists
- Interleukins
- Interferons
- Tumor-infiltrating lymphocytes
- Lymphokine-activated killer cell therapy
- Gene therapy
- Antisense therapy
- No prior hormonal therapy for brain tumor
- More than 14 days since prior and no concurrent steroid therapy for patients with low-grade (grade I or II) astrocytoma
- Prior glucocorticoid therapy allowed
Exclusion
Key Trial Info
Start Date :
July 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00999622
Start Date
July 1 2004
Last Update
May 28 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.